| Q90322472 | Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS |
| Q53326795 | Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. |
| Q46760321 | Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study |
| Q36882707 | Hospitalization rates and discharge status in multiple sclerosis |
| Q38777286 | Intervening to reduce the risk of future disability from multiple sclerosis: are we there yet? |
| Q34317484 | Kynurenines in the CNS: recent advances and new questions. |
| Q38364965 | Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases |
| Q38172961 | Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system |
| Q47200732 | Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments |
| Q30659100 | Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis |
| Q34577661 | No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis |
| Q64089595 | Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis |
| Q64116166 | Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study |
| Q36803649 | Role of oral teriflunomide in the management of multiple sclerosis. |
| Q41197212 | Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials. |
| Q41877062 | Teriflunomide attenuates immunopathological changes in the dark agouti rat model of experimental autoimmune encephalomyelitis |
| Q24186016 | Teriflunomide for multiple sclerosis |
| Q24202177 | Teriflunomide for multiple sclerosis |
| Q38891855 | Teriflunomide for multiple sclerosis in real-world setting. |
| Q38289353 | Teriflunomide for the treatment of relapsing-remitting multiple sclerosis |
| Q39114065 | Teriflunomide in multiple sclerosis: an update |
| Q37117605 | Teriflunomide in relapsing multiple sclerosis: therapeutic utility |
| Q64229136 | Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients |
| Q38205268 | Teriflunomide: a novel oral treatment for relapsing multiple sclerosis |
| Q26781285 | Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis |
| Q38160410 | Teriflunomide: a review of its use in relapsing multiple sclerosis |
| Q39195628 | The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multip |
| Q48359339 | The neuroprotective effect of mesenchymal stem cells on an experimentally induced model for multiple sclerosis in mice. |
| Q47800390 | The tension between early diagnosis and misdiagnosis of multiple sclerosis |
| Q30354658 | Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis. |
| Q34330211 | Treating multiple sclerosis with monoclonal antibodies: a 2013 update |
| Q37884434 | Treatment of multiple sclerosis: current concepts and future perspectives |
| Q86835988 | [Teriflunomide for treatment of multiple sclerosis] |